| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2022: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2021: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2018: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
|
|---|
| Outline of Final Research Achievements |
This study aims to develop a point-of-care testing for prorenin, an early marker of diabetic complications, and to investigate the pathobiochemical significance of prorenin in diabetes pathology through a collaboration between India, Bangladesh and Japan. We identified a new antibody pair that sandwiches the antigen prorenin and produced recombinant single-chain variable fragment that retains antigen recognition capability, even with a small molecular weight. We improved a prorenin measurement method based on renin enzymatic activity. Additionally, we found that non-coding single nucleotide variants of genes involved in renin-angiotensin-aldosterone system, which regulate blood pressure, may be significant risk factors for hypertension and type 2 diabetes-associated hypertension.
|
